This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009).

The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease has resulted in a change in the guidance. Specifically:

  • donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer’s disease, and
  • memantine is now recommended as an option for managing moderate Alzheimer’s disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer’s disease.
  • National Institute for Health and Care Excellence (NICE) accreditation logo